NeoGenomics, Inc. (NEO) News

NeoGenomics, Inc. (NEO): $49.51

0.60 (+1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NEO News Items

NEO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NEO News Highlights

  • For NEO, its 30 day story count is now at 13.
  • Over the past 22 days, the trend for NEO's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • LINK, BIO and CRWD are the most mentioned tickers in articles about NEO.

Latest NEO News From Around the Web

Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.

NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021

FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021.

Yahoo | April 7, 2021

NeoGenomics To Snap Up Trapelo Health; Street Says Buy

Genetic testing and contract research provider NeoGenomics announced the acquisition of Trapelo Health for $65 million. The latter is focused on precision oncology. NeoGenomics’ (NEO) Chairman and CEO, Douglas M. VanOort said, “The addition of Trapelo to NeoGenomics significantly enhances our ability to provide customers with information to help them answer difficult and complex questions related to precision oncology biomarker testing and treatment options.” VanOort further added, “We plan to make the Trapelo solution broadly available to providers, payers and laboratories to enable precision oncology to be available across all healthcare settings.

Kailas Salunkhe on TipRanks | March 24, 2021

The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS) (announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Organogenesis Holdings Inc. (NASDAQ: ORGO) Soliton, Inc. (NASDAQ: SOLY) Radius Health, Inc. (NASDAQ: RDUS) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Connect Biopharma Holdings Limited (NASDAQ: CNTB) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH) (IPOed Friday) Frequency Therapeutic...

Yahoo | March 24, 2021

NeoGenomics Agrees to Acquire Trapelo Health

Clinical Decision Support to Enable Precision Oncology FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc.

Yahoo | March 24, 2021

NeoGenomics: Well-Funded Cancer Diagnostics Play Needs To Execute On Ambitious Growth Plan

Photo by ipopba/iStock via Getty ImagesInvestment Thesis In my last post on NeoGenomics (NEO) in June last year I recommended the company's shares as an investment opportunity and set a price of >$50 for 2021. I'm pleased to report that Neo stock passed $50 in early December and rose as...

Edmund Ingham on Seeking Alpha | March 19, 2021

Thinking about trading options or stock in Crowdstrike Holdings, NeoGenomics, General Electric, Mcdonald's, or Wells Fargo?

NEW YORK, March 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRWD, NEO, GE, MCD, and WFC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…

PR Newswire | March 17, 2021

Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study. NeoGenomics is a leading provider of next-generation sequencing (NGS) performing more than 50,000 NGS tests per year.

Yahoo | March 16, 2021

NeoGenomics and Elevation Oncology Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion PanelsFORT MYERS, FL and NEW YORK, NY / ACCESSWIRE / March 16, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, and Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study.

Yahoo | March 16, 2021

NeoGenomics To Participate In The Virtual Raymond James 42nd Annual Institutional Investors Conference

MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chief Financial Officer Kathryn McKenzie and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual Raymond James 42nd Annual Institutional Investors Conference 2021, on Wednesday, March 3, 2021 at 10:50am ET.

Yahoo | March 1, 2021

NeoGenomics to Participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference

MYERS, FL / ACCESSWIRE / February 16, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and .

Yahoo | February 16, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.655 seconds.